Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Cemtrex, Inc. (CETX) has increased by 284% to $11.79 - Treasure Global Inc. (TGL) has risen by 135% to $59.83 - Top Wealth Group Holding Limited (TWG) is up 95% at $11.73 - Fulcrum Therapeutics, Inc. (FULC) has gained 49% to $13.29 - MetaVia Inc. (MTVA) is up 33% at $10.90 - Kymera Therapeutics, Inc. (KYMR) has increased by 31% to $87.58 - Confluent, Inc. (CFLT) is up 27% at $29.40 - Immix Biopharma, Inc. (IMMX) has risen by 23% to $6.85 - Nurix Therapeutics, Inc. (NRIX) is up 18% at $21.46 - SU Group Holdings Limited (SUGP) has increased by 15% to $6.44 [3] Premarket Losers - SMX (Security Matters) Public Limited Company (SMX) has decreased by 27% to $242.01 - Meihua International Medical Technologies Co., Ltd. (MHUA) is down 27% at $10.20 - Polyrizon Ltd. (PLRZ) has declined by 16% to $10.90 - Fly-E Group, Inc. (FLYE) is down 16% at $6.90 - Sensei Biotherapeutics, Inc. (SNSE) has decreased by 14% to $8.29 - Kentucky First Federal Bancorp (KFFB) is down 10% at $4.00 - Arteris, Inc. (AIP) has declined by 7% to $16.27 - Fusion Fuel Green PLC (HTOO) is down 6% at $3.89 - Kamada Ltd. (KMDA) has decreased by 5% to $6.69 - iOThree Limited (IOTR) is down 5% at $3.11 [4]

Stock Performance - Sensei Biotherapeutics Inc. (NASDAQ:SNSE) experienced a significant increase of 62.88% in after-hours trading, reaching a price of $17.20, following a closing price of $10.56, which was up 21.38% on Thursday [1] - The stock has gained 2.52% year to date and 46.26% over the past six months, indicating strong performance [3] - The market capitalization of Sensei Biotherapeutics is $13.32 million, with its stock trading between $5 and $18.35 over the past 52 weeks [3] Shareholder Activity - Cambrian BioPharma Inc., a 10% shareholder, filed two Form 144 filings with the SEC, indicating the intent to sell 27,066 common shares valued at $235,744 [1] - The proposed sale represents shares from a total of 1.26 million common shares outstanding [2]

Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei Biotherapeutics Inc. (SNSE) soared 62.9% to $17.20 after hours, extending momentum from its 21.4% rise at the close. The company did not release fresh updates on Thursday, but last month reported a narrower third-quarter net loss of $4.6 million compared with $7.3 million a year earlier. Sensei ended September with $25.0 million in cas ...

Company Strategy and Operations - The company announced the discontinuation of its lead product candidate, solnerstotug, and is exploring strategic alternatives, including asset sales and potential mergers[86]. - The company has discontinued the development of solnerstotug and is exploring strategic alternatives, which may include asset sales or a merger[115]. - A workforce reduction of approximately 65% was implemented to preserve cash, with expected aggregate cash charges of about $1.6 million related to severance and termination expenses[87]. - The company expects to continue incurring net losses and negative cash flows for the foreseeable future, with a decrease in research and development and general administrative expenses anticipated[92]. Financial Performance - The company has incurred significant operating losses, reporting a net loss of $16.4 million for the nine months ended September 30, 2025, compared to a net loss of $22.4 million for the same period in 2024[91]. - The net loss for the nine months ended September 30, 2025, was $16.4 million, an improvement of $6.0 million compared to a net loss of $22.4 million for the same period in 2024[110]. - As of September 30, 2025, the company had an accumulated deficit of $278.4 million[91]. - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $25.0 million, with an accumulated deficit of $278.4 million[114]. - Net cash used in operating activities was $16.6 million for the nine months ended September 30, 2025, compared to $18.9 million in 2024[117]. Expenses - Research and development expenses decreased to $2.5 million for the three months ended September 30, 2025, down from $4.6 million in the same period in 2024, reflecting a reduction of $2.1 million[107]. - General and administrative expenses were $2.3 million for the three months ended September 30, 2025, compared to $3.2 million for the same period in 2024, a decrease of $0.9 million[108]. - For the nine months ended September 30, 2025, total operating expenses were $17.3 million, a decrease of $7.0 million compared to $24.3 million in 2024, driven by reductions in research and development and general administrative expenses[110]. - Research and development expenses were $8.8 million for the nine months ended September 30, 2025, down from $14.1 million in 2024, reflecting a decrease of $5.3 million primarily due to lower personnel costs and lab supply purchases[111]. - General and administrative expenses decreased to $8.5 million for the nine months ended September 30, 2025, from $10.2 million in 2024, a reduction of $1.7 million mainly due to lower personnel costs[112]. Going Concern and Financial Outlook - There is substantial doubt about the company's ability to continue as a going concern, as it will not have sufficient cash to fund operations beyond one year from the report date[93]. - The company expects that existing cash and cash equivalents will be insufficient to fund operations beyond one year from the issuance of the financial statements, raising substantial doubt about its ability to continue as a going concern[129]. - The company has not recorded any income tax benefits for net losses incurred, as it believes it is unlikely to realize net operating loss carryforwards[105]. Other Income - Other income decreased to $0.3 million for the three months ended September 30, 2025, down from $0.6 million for the same period in 2024, primarily due to a decrease in interest income[109]. Reporting Classification - The company is classified as a smaller reporting company and is not required to provide detailed market risk disclosures[141].

Financial Results - Sensei Biotherapeutics, Inc. announced its financial results for the quarter ended September 30, 2025[4] - A press release detailing the financial results was issued on November 14, 2025[4] - The financial results include key metrics that will be detailed in the attached press release[4] - The report includes an exhibit with further financial details[6] Company Classification - The company is classified as an emerging growth company under the Securities Act[3] - The report is not deemed "filed" under the Securities Exchange Act of 1934[5] Company Information - The company is headquartered at 1405 Research Blvd, Suite 125, Rockville, MD 20850[1] - The common stock of Sensei Biotherapeutics is traded on The Nasdaq Stock Market under the symbol SNSE[2] Report Details - The report was signed by Christopher W. Gerry, General Counsel and Secretary[9] - The filing date of the report is November 14, 2025[9]

Core Insights - Sensei Biotherapeutics, Inc. has reported its financial results for Q3 2025, highlighting a significant strategic shift in its operations [1][4][5] - The company has decided to discontinue the development of its lead product candidate, solnerstotug, and is exploring various strategic alternatives to maximize shareholder value [2][3] Financial Performance - As of September 30, 2025, the company's cash, cash equivalents, and marketable securities totaled $25.0 million, down from $41.3 million at the end of 2024 [4] - Research and Development (R&D) expenses for Q3 2025 were $2.5 million, a decrease from $4.6 million in Q3 2024, primarily due to lower personnel and facility costs [4] - General and Administrative (G&A) expenses also decreased to $2.3 million in Q3 2025 from $3.2 million in Q3 2024, attributed to reduced personnel costs [5] - The net loss for Q3 2025 was $4.6 million, compared to a net loss of $7.3 million in the same quarter of the previous year [5][8] Strategic Review and Workforce Reduction - The company has implemented a workforce reduction of approximately 65% to conserve cash while it reviews strategic alternatives [2][3] - A small team will remain to assist in exploring these alternatives and managing the cessation of development activities [3] Balance Sheet Highlights - As of September 30, 2025, total assets were reported at $27.6 million, down from $45.4 million at the end of 2024 [10] - Total liabilities decreased to $4.6 million from $7.0 million, while total stockholders' equity fell to $23.0 million from $38.4 million [10]

Core Viewpoint - Sensei Biotherapeutics has decided to discontinue the development of solnerstotug and is initiating a strategic review to maximize shareholder value, which may include various options such as asset sales or mergers [1][3]. Company Overview - Sensei Biotherapeutics is a clinical-stage biotechnology company focused on developing next-generation therapeutics for cancer patients [4]. Strategic Review and Workforce Reduction - The company plans to implement a workforce reduction to preserve cash, retaining a small team to assist in exploring strategic alternatives and managing the cessation of development activities [2]. - The strategic review may lead to various outcomes, including a sale of assets, licensing arrangements, or a merger, but there is no definitive timeline for this process [1][3]. Clinical Development Status - Solnerstotug has shown clinical activity in a patient population with significant unmet needs, but the company has decided not to initiate new clinical studies due to funding needs and the current capital markets environment [3].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - AlphaVest Acquisition Corp (ATMV) is up 71% at $14.24 [3] - BranchOut Food Inc. (BOF) is up 44% at $3.04 [3] - rYojbaba Co., Ltd. (RYOJ) is up 35% at $5.14 [3] - GSI Technology, Inc. (GSIT) is up 25% at $16.24 [3] - Jowell Global Ltd. (JWEL) is up 18% at $2.02 [3] - General Motors Company (GM) is up 9% at $63.68 [3] - Crown Holdings, Inc. (CCK) is up 8% at $103.00 [3] - Spero Therapeutics, Inc. (SPRO) is up 8% at $2.49 [3] - Sunrun Inc. (RUN) is up 6% at $21.90 [3] - Foxx Development Holdings Inc. (FOXX) is up 5% at $4.50 [3] Premarket Losers - Neuphoria Therapeutics Inc. (NEUP) is down 66% at $5.19 [4] - New Era Energy & Digital, Inc. (NUAI) is down 9% at $5.09 [4] - Odyssey Marine Exploration, Inc. (OMEX) is down 8% at $3.28 [4] - Carbon Revolution Public Limited Company (CREV) is down 7% at $4.86 [4] - Coeur Mining, Inc. (CDE) is down 7% at $20.38 [4] - Hecla Mining Company (HL) is down 6% at $13.50 [4] - Verrica Pharmaceuticals Inc. (VRCA) is down 6% at $4.12 [4] - Sensei Biotherapeutics, Inc. (SNSE) is down 5% at $10.06 [4] - Whitehawk Therapeutics, Inc. (WHWK) is down 5% at $2.52 [4] - Greenidge Generation Holdings Inc. (GREE) is down 5% at $2.07 [4]

Summary of Sensei Biotherapeutics Conference Call Company Overview - **Company**: Sensei Biotherapeutics (NasdaqGM:SNSE) - **Event Date**: October 20, 2025 - **Focus**: Update on Solnestretug, a VISTA-targeting antibody in immuno-oncology Key Points Industry Context - **Immuno-Oncology**: The call marks a significant milestone for the field, particularly regarding VISTA-targeting therapies, which have not previously demonstrated progression-free survival data in PD1-resistant tumors [2][56] Clinical Data and Findings - **Solnestretug**: - Represents the first progression-free survival data for any VISTA-targeting antibody [2] - Demonstrated clinical activity, durability, and tolerability, suggesting a differentiated mechanism of action [2] - Designed to selectively reverse immunosuppression in the tumor microenvironment, avoiding systemic toxicity [4][6] - **Clinical Trials**: - Phase one dose escalation showed no dose-limiting toxicity, reaching a top dose of 15 mg/kg [7][8] - Combination therapy with cemiplimab was well tolerated, with a six-month progression-free survival rate of 37% for patients previously treated with immunotherapy [15][21] - Notably, 50% of patients receiving the 15 mg/kg dose had a six-month progression-free survival [16][21] Safety Profile - **Adverse Events**: - Low-grade cytokine release syndrome was the only notable class-related adverse event, with no grade 3 or 4 adverse events attributed to Solnestretug [12][48] - The safety profile was consistent with that of single-agent cemiplimab, indicating a well-tolerated regimen [48][56] Market Opportunity - **Commercial Potential**: - PD1-targeted therapies generate over $45 billion annually, with significant unmet needs in secondary resistance cases [4][5] - VISTA's expression across various cancer types presents a broad therapeutic potential [5] Future Plans - **Phase Two Studies**: - Planned initiation in early 2026, focusing on hot tumor settings and potentially leading to accelerated approval in the PD1-resistant population [25][29] - Two-study approach: one randomized study in non-small cell lung cancer and a single-arm study in Merkel cell carcinoma [26][27] Regulatory Considerations - **FDA Engagement**: - Ongoing discussions with the FDA regarding phase two study design and potential for breakthrough therapy designation [54] Conclusion - **Overall Impact**: - Solnestretug represents a significant advancement in immuno-oncology, offering a new therapeutic path for patients with secondary resistance to existing therapies [56][57] - **Future Outlook**: - The company is optimistic about the potential of Solnestretug to redefine treatment options in the immuno-oncology landscape [57]

Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors October 20, 2025 Presenters: Dr. Kyriakos Papadopoulos Co-Director of Clinical Research START, San Antonio Principal Investigator for Ph1 trial of Solnerstotug John Celebi Chief Executive Officer Ron Weitzman Chief Medical Officer Disclaimer This presentation has been prepared by Sensei Biotherapeutics, Inc. (the "Company," "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be com ...